{"id":727621,"date":"2023-02-01T08:20:44","date_gmt":"2023-02-01T13:20:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/"},"modified":"2023-02-01T08:20:44","modified_gmt":"2023-02-01T13:20:44","slug":"bolt-biotherapeutics-to-present-at-february-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/","title":{"rendered":"Bolt Biotherapeutics to Present at February Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>REDWOOD CITY, Calif., Feb.  01, 2023  (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Guggenheim Healthcare Talks 2023 Oncology Day<br \/><\/strong>Fireside chat on Wednesday, Feb. 8 at 12:55 p.m. PST (3:55 p.m. EST)<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <strong>Virtual SVB Securities Global Biopharma Conference 2023<br \/><\/strong>Fireside chat on Thursday, Feb. 16 at 12:40 p.m. PST (3:40 p.m. EST)<\/li>\n<\/ul>\n<p>Live webcasts of the fireside chats will be available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N9KNSOjgnk8lxQA8tXxqYpCXawKJ95XVQdK7A8Kt0fhUXDIzIkMyu28Mdd8k7fmLpcv1C4XVDZ_iFJDlYAdSPa9U0pU4NpqKjUpLGleY_vukPA8qcNDNKCxQF_uzkhlx9gsUA4SDMAGzFGwiBXvevQFtmkrEpJ0prwITHxMj1pc=\" rel=\"nofollow noopener\" target=\"_blank\">Events and Presentations<\/a> page of Bolt\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oIa5Nd8JQqKX2o4YwIqxWAl2obvDD4izZ3oDnc-1tef2KiTCsTaPHB7QSsgl0ACsgSf1ChDpdBlJctXZ87N8j1JB-1FgRG6X5wRda3sInW2RRDmD7AGza6wKR6XGRGLZ-nbWPAADeknnZLou7pvfW3TFATV06_gCgBbxN-n3bP5inKc8fhHYwweoh7IMymG1BjA_rjW38e9XwQGCraybaBB0VPAfs0j7hozsmHqBLKw=\" rel=\"nofollow noopener\" target=\"_blank\">www.boltbio.com<\/a>. Archived replays will be available for 30 days following the event.<\/p>\n<p>\n        <strong>About Bolt Biotherapeutics, Inc.<\/strong><br \/>\n        <br \/>Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics\u2019 pipeline candidates are built on the Company\u2019s deep expertise in myeloid biology and cancer drug development. The Company\u2019s pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Bolt Biotherapeutics is currently progressing BDC-1001 through a Phase 1\/2 dose-escalation clinical trial, as a monotherapy and in combination with Bristol Myers Squibb\u2019s immune checkpoint inhibitor, Opdivo<sup>\u00ae<\/sup> (nivolumab), in a variety of HER2-expressing solid tumors. Bolt Biotherapeutics is advancing BDC-3042, an agonist antibody targeting Dectin-2, through IND-enabling studies. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. Bolt Biotherapeutics is leveraging its ability to engineer and optimize novel applications of its Boltbody ISACs to develop multiple immuno-oncology candidates through strategic collaborations with leading biopharmaceutical companies. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MprHUEXLFQVAjWTUs-0MwYtUBhXjmoiPmG4YyTHmOTH1sAbmK6ChbFjr4iCKKJBvDxbHluWS9icsPP5J5PJyDUznhx-IEtKaPo4IdijUecQ=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.boltbio.com\/<\/a><\/p>\n<p>\n        <strong>Investor Relations and Media Contacts:<\/strong><br \/>\n        <br \/>Karen L. Bergman<br \/>Vice President, Communications and Investor Relations<br \/>Bolt Biotherapeutics, Inc.<br \/>650-665-9295<br \/>kbergman@boltbio.com<\/p>\n<p>Sarah McCabe<br \/>Stern Investor Relations, Inc.<br \/>212-362-1200<br \/>sarah.mccabe@sternir.com<\/p>\n<p>David Melamed<br \/>Russo Partners, LLC<br \/>212-845-4225<br \/>david.melamed@russopartnersllc.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/M2FkMGI0MTctNWFhOS00YjBjLWI0ZGUtYWM4NzAwMzc1OGVmLTEyMTM0NDI=\/tiny\/Bolt-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February: Guggenheim Healthcare Talks 2023 Oncology DayFireside chat on Wednesday, Feb. 8 at 12:55 p.m. PST (3:55 p.m. EST) Virtual SVB Securities Global Biopharma Conference 2023Fireside chat on Thursday, Feb. 16 at 12:40 p.m. PST (3:40 p.m. EST) Live webcasts of the fireside chats will be available on the Events and Presentations page of Bolt\u2019s website at\u00a0www.boltbio.com. Archived replays will be available for 30 days following the event. About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Bolt Biotherapeutics to Present at February Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-727621","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Bolt Biotherapeutics to Present at February Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bolt Biotherapeutics to Present at February Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February: Guggenheim Healthcare Talks 2023 Oncology DayFireside chat on Wednesday, Feb. 8 at 12:55 p.m. PST (3:55 p.m. EST) Virtual SVB Securities Global Biopharma Conference 2023Fireside chat on Thursday, Feb. 16 at 12:40 p.m. PST (3:40 p.m. EST) Live webcasts of the fireside chats will be available on the Events and Presentations page of Bolt\u2019s website at\u00a0www.boltbio.com. Archived replays will be available for 30 days following the event. About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for &hellip; Continue reading &quot;Bolt Biotherapeutics to Present at February Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T13:20:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Bolt Biotherapeutics to Present at February Investor Conferences\",\"datePublished\":\"2023-02-01T13:20:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/\"},\"wordCount\":315,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/\",\"name\":\"Bolt Biotherapeutics to Present at February Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=\",\"datePublished\":\"2023-02-01T13:20:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bolt-biotherapeutics-to-present-at-february-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bolt Biotherapeutics to Present at February Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Bolt Biotherapeutics to Present at February Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Bolt Biotherapeutics to Present at February Investor Conferences - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) &#8212; Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that management will participate in two upcoming conferences in February: Guggenheim Healthcare Talks 2023 Oncology DayFireside chat on Wednesday, Feb. 8 at 12:55 p.m. PST (3:55 p.m. EST) Virtual SVB Securities Global Biopharma Conference 2023Fireside chat on Thursday, Feb. 16 at 12:40 p.m. PST (3:40 p.m. EST) Live webcasts of the fireside chats will be available on the Events and Presentations page of Bolt\u2019s website at\u00a0www.boltbio.com. Archived replays will be available for 30 days following the event. About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for &hellip; Continue reading \"Bolt Biotherapeutics to Present at February Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-01T13:20:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Bolt Biotherapeutics to Present at February Investor Conferences","datePublished":"2023-02-01T13:20:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/"},"wordCount":315,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/","name":"Bolt Biotherapeutics to Present at February Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=","datePublished":"2023-02-01T13:20:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0MDE0OSM1Mzg0NDk1IzIyMDE4ODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bolt-biotherapeutics-to-present-at-february-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Bolt Biotherapeutics to Present at February Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=727621"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/727621\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=727621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=727621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=727621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}